Citations

Clear

1053 citation(s) found for "Andre, F".

Brd4 Inactivation Increases Adenoviral Delivery of BMP2 for Paracrine Stimulation of Osteogenic Differentiation as a Gene Therapeutic Concept to Enhance Bone Healing
Paradise, Christopher R. , Vega, Rodolfo E. De la , Galvan, M. Lizeth, Carrasco, Margarita E., Thaler, Roman , Wijnen, André J. van , Dudakovic, Amel , De La Vega, Rodolfo E, van Wijnen, Andre J , van Wijnen, Andre J , Dudakovic, Amel , De La Vega, Rodolfo E

Mayo Clinic

JBMR Plus | June 3, 2021 | Volume: 5 | Issue: 10 | Pages: No page available

10.1002/jbm4.10520 | PMID 34693189 Get It

ABSTRACTBromodomain (BRD) proteins are histone code interpreters that recognize acetylated lysines and link the dynamic state of chromatin with the transcriptional machinery. Here, we demonstrate that ablation of the Brd4 gene in primary mouse bone marrow–derived mesenchymal stem cells via a conditional Brd4fl/fl allele suppresses osteogenic lineage commitment. Remarkably, loss of Brd4 function also enhances expression of genes in engineered adenoviral vectors, including Cre recombinase and green fluorescent protein (GFP). Similarly, vector‐based expression of BMP2 mRNA and protein levels are enhanced upon Brd4 depletion in cells transduced with an adenoviral vector that expresses BMP2 (Ad‐BMP2). Importantly, Brd4 depletion in MC3T3‐E1 and human adipose‐derived mesenchymal stem cells (AMSCs) transduced with Ad‐BMP2 enhances osteogenic differentiation of naïve MC3T3‐E1 cells via paracrine mechanisms based on transwell and conditioned medium studies. Our studies indicate that Brd4 depletion enhances adenoviral transgene expression in mammalian cells, which can be leveraged as a therapeutic strategy to improve viral vector‐based gene therapies. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.
Kopečková, Kateřina , Pichler, Petra , Klöpfer, Pia, Brackertz, Bettina, Lohrmann, E., Lahiry, Anirban , Shah, Neha , Brugger, Wolfram, Burke, John M. , Nowakowski, Grzegorz S. , Belada, David , Bergua, Juan , André, Marc , Persona, Ernesto Pérez

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 7540-7540

10.1200/jco.2021.39.15_suppl.7540 Get It

7540 Background: Tafasitamab is a humanized, Fc-modified anti-CD19 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity and phagocytosis. It is FDA-approved with LEN for adult patients (pts) with relapsed/refractory (R/R) DLBCL ineligible for autologous stem cell transplantation. First-MIND (NCT04134936) is a Phase Ib, open-label, randomized study of tafa + R-CHOP or tafa + LEN + R-CHOP in newly diagnosed DLBCL. Methods: Eligible pts were ≥18 years, treatment-naïve, with histologically confirmed DLBCL not otherwise specified, international prognostic index (IPI) 2–5 and ECOG performance status (PS) 0–2. Pts with known double- or triple-hit and transformed lymphoma were excluded. Treatment (Tx) comprised six 21-day cycles of tafa (12 mg/kg IV, Day [D] 1, 8, 15) + R-CHOP (arm A) or tafa (12 mg/kg IV, D1, 8, 15) + LEN (25 mg orally, D1–10) + R-CHOP (arm B). G-CSF and VTE prophylaxis was mandatory. Primary objective is safety; secondary objectives are ORR, PET-CR rate at end of Tx, PFS, long-term safety, pharmacokinetics, immunogenicity. Results: From Dec 2019 to Aug 2020, 83 pts were screened in Europe and the US; 66 were randomized (33 per arm). Data cut-off for this analysis: 9 Dec 2020; study is ongoing. Median age was 64.5 years (range 20–86). Overall, 30% (20/66) of pts were ≥70 years and many had high-risk disease: IPI 2 29%, IPI 3 46%, IPI 4 26%. ECOG PS: 47% of pts were ECOG PS 0, 44% PS 1, 9% PS 2. Most pts had stage III/IV disease (92%); 46% had bulky disease. All pts experienced a treatment-emergent adverse event (TEAE). Grade ≥3 neutropenia and thrombocytopenia occurred in 54.5% and 12.1% (arm A) and 66.7% and 30.3% (arm B) of pts, respectively (Table). Serious TEAEs occurred in 42.4% (arm A) and 51.5% (arm B) of pts. There were three deaths, unrelated to tafa and/or LEN (sepsis, urosepsis, and COVID-19 pneumonia). R-CHOP dose intensity was maintained in both arms. Among 60 pts who completed tumor assessments after cycle 3, ORR was 89.7% (arm A) and 93.5% (arm B). Conclusions: These data suggest R-CHOP + tafa or tafa + LEN is tolerable in pts with Tx-naïve DLBCL and that R-CHOP dosing is not affected. Toxicities are similar to those expected with R-CHOP or R-CHOP + LEN. Updated safety and early efficacy data will be presented at the conference. Clinical trial information: NCT04134936. [Table: see text]
Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.
Yothers, Greg , Haller, Daniel G. , Gramont, Aimery de , Twelves, Chris , Tomita, Naohiro , Goldberg, Richard M. , Yothers, Greg , Jin, Zhaohui , Dixon, Jesse G. , Parekh, Hiral D. , Sinicrope, Frank A. , Schmoll, Hans‐Joachim , Kerr, Rachel , Taı̈eb, Julien , Cutsem, Eric Van , Saltz, Leonard B. , Yoshino, Takayuki , André, Thierry , Mahipal, Amit , George, Thomas J. , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 3597-3597

10.1200/jco.2021.39.15_suppl.3597 Get It

3597 Background: Colon cancer (CC) incidence and mortality have decreased since the 1970s, but the incidence in young adults (20-49 years) is increasing. There are limited data suggesting that, as a group, patients with early onset CRC (eoCC) may have different phenotypic characteristics compared to those with late onset CRC (loCC, age ≥ 50 years). Methods: Individual patient data on 35,713 subjects with stage III CC from 25 randomized studies (recruiting between 1987 and 2009) in the ACCENT database were pooled. The distributions of demographics, clinicopathological features, biomarkers, and outcome data were summarized by age group. Overall survival (OS), disease-free survival (DFS), recurrence free rate (RFR), and survival after recurrence (SAR) were assessed by Kaplan-Meier curves and Cox models stratified by treatment arms within studies, adjusting for gender, race, body mass index, performance status, disease stage, grade, risk group, number of lymph nodes examined, disease sidedness and molecular markers. Results: Using a 5% difference between age groups as the clinically meaningful cutoff, patients with stage III eoCC (n = 6246) had similar distributions according to gender, race, PS, risk group, tumor sidedness and T/N stage compared to those with loCC (n = 29467). Patients with eoCC were significantly less likely to be overweight (30.2% vs 36.2%) but more commonly had ≥ 12 lymph nodes resected (69.5% vs 58.7%). The eoCC tumors were more frequently mismatch repair deficient (16.4% vs 11.5%), and less likely to have BRAFV600E (5.6% vs 14.0%), suggesting a higher frequency of Lynch syndrome in eoCC. In univariate analysis, patients with stage III eoCC had significantly better OS, DFS, and SAR; the difference between 3-year DFS and RFR strongly suggests the OS/DFS difference between these the eoCC and loCC may be due to increased competing risks and comorbidities in patients with loCC. In multivariate analysis, age at onset lost its prognostic value when outcome was adjusted for molecular markers. The clear relation between age of onset and KRAS/BRAF status was confirmed in the interaction analysis. Conclusions: Tumor biology was an important determinant of prognosis regardless of patient age. In multivariate analysis age of onset was not a statistically significant determinant of outcome.[Table: see text]
Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.
Meyers, Jeffrey P., Sobrero, Alberto F. , Shields, Anthony F. , Souglakos, Ioannis , Smyth, Elizabeth Catherine, Lordick, Florian , Moehler, Markus, Harkin, Andrea , Yamanaka, Takeharu , Boukovinas, Ioannis , Grothey, Axel, Ben‐Aharon, Irit , EORTC, Adolescent and Young Adult Gastrointestinal Cancer Task Force, Fontana, Elisa , Iveson, Timothy , Taı̈eb, Julien , Yoshino, Takayuki , Labianca, Roberto , Meyerhardt, Jeffrey A. , André, Thierry , Shi, Qian , EORTC, Adolescent and Young Adult Gastrointestinal Cancer Task Force

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 3517-3517

10.1200/jco.2021.39.15_suppl.3517 Get It

3517 Background: Incidence of early-onset colorectal cancer (eoCRC, age < 50) is steadily increasing. Decisions on adjuvant treatment (adjTx) regimen and duration should consider tx adherence, toxicity (tox) and expected outcomes in a population with life-expectancy longer than late onset CRC (loCRC, age ≥ 50). Methods: Individual patient data from stage II/III patients (pts) from 6 randomised trials in the IDEA database were used to compare characteristics, tx adherence, and adverse events of eoCRC to loCRC. To reduce the confounder of non-cancer-related deaths due to age/co-morbidities, time-to-recurrence (TTR) and cancer-specific survival (CSS) were compared by stratified Gay k-sample test. 5-year cancer-specific mortality (CSM) rate were estimated by adjusted cumulative incidence function. 3-year relapse-free survival (RFS) rate were compared by stratified and adjusted COX models. Results: Out of 16,349 pts included, 1564 (9.6%) were eoCRC. Compared to loCRC, eoCRC had lower percent of male pts (51% vs 57%, p < 0.01) better performance status (PS0 86% vs 80%, p < 0.01), similar T stage distribution (% T1-3/T4: 76/24 vs 77/23, p = 0.97), higher rate of N2 disease (24% vs 22%, p < 0.01), more likely to complete pre-planned duration of adjTx (83.2% vs 78.2%, p < 0.01) and received a higher tx intensity especially with 6 month tx (mean oxaliplatin dose intensity 75% vs 72%, p < 0.01; capecitabine 85% vs 78%, p < 0.01; 5FU 85% vs 82% p < 0.01). Gastrointestinal tox was more common in eoCRC (any grade nausea 58% vs 45%, p < 0.01; any grade vomiting 22% vs 16%, p < 0.01); haematological tox was more frequent in loCRC (62% vs, 69%, p = < 0.01); any grade neuropathy rate was similar (75%). Significant interaction was found between age and T stage for TTR (p = 0.04). Clinical outcome estimates and comparisons are shown in Table. Notably, high risk stage III (T4/N2) eoCRC had significantly lower 3-y RFS rate (54% vs 64%, HRadj 0.74, p < 0.01). Conclusions: eoCRC have better tx adherence than loCRC, as expected. While in high risk stage II and low risk stage III, cancer-specific outcomes are not different, in high risk stage III young age is negatively prognostic and associated with significantly higher relapse rate and risk of CRC death; this is despite a higher administered adjTx-intensity, suggesting a more aggressive disease biology. Clinical trial information: NCT00749450 (SCOT); NCT00646607 (TOSCA); NCT01150045 (CALGB/SWOG 80702); NCT00958737 (IDEA France) [Table: see text]
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
Baird, Richard D. , Ettl, Johannes , Joy, Anil A. , Neven, Patrick , Haddad, Vincent , Walding, Andrew, Miralles, Manuel Selvi , Bartlett, Cynthia Huang , Im, Seock‐Ah , Hamilton, Erika , Llombart‐Cussac, Antonio , Goetz, Matthew P. , Iwata, Hiroji , André, Fabrice

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: TPS1101-TPS1101

10.1200/jco.2021.39.15_suppl.tps1101 Get It

TPS1101 Background: More than two thirds of patients with advanced breast cancer (ABC) have estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) tumors. Current standard-of-care first-line treatments include an aromatase inhibitor (AI) or fulvestrant, a selective ER degrader (SERD), combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Concurrent use of luteinizing hormone-releasing hormone (LHRH) agonists is recommended for men and premenopausal women with ABC. Nevertheless, almost all ABCs eventually become resistant to endocrine therapy (ET) and the disease is incurable. New therapies are needed to combat ET resistance, maintain patient quality of life (QoL), and delay the need for chemotherapy. AZD9833 (camizestrant) is an orally bioavailable, highly potent, next-generation SERD that demonstrated anti-cancer properties across a range of preclinical models, including those with ER-activating mutations (Scott et al, 2020). A phase I study (SERENA-1) has demonstrated that AZD9833 is well tolerated and has a promising antitumor profile when administered alone or in combination with palbociclib, a CDK4/6 inhibitor (Baird et al, SABCS 2020). SERENA-4 (NCT04711252) is a randomized, multicenter, double-blind, phase III trial to evaluate the safety and efficacy of AZD9833 in combination with palbociclib for patients with ER+ HER2− ABC who have not received any systemic treatment in the advanced disease setting. Methods: SERENA-4 will enroll 1,342 patients with de novo or recurrent ER+ HER2– ABC who have not previously received systemic treatment for their locoregionally recurrent or metastatic disease. Patients with recurrent disease must have received adjuvant AI or tamoxifen therapy for at least 24 months without relapse. Patients will be randomized 1:1 to receive orally either (a) AZD9833 (75 mg, once daily), palbociclib (125 mg, once daily for 21 days followed by 7 days off treatment) and anastrozole-matching placebo (once daily) or (b) anastrozole (1 mg, once daily), palbociclib (same as active arm), and AZD9833-matching placebo (once daily). Premenopausal women and men will also receive LHRH agonists. The primary endpoint will be progression-free survival (PFS; up to 5 years). Secondary endpoints will include overall survival (up to 8 years), length of second PFS period, objective response, time to chemotherapy, and changes in QoL measures. Enrollment began in January 2021. Acknowledgments: We thank Rose Goodchild, PhD, of Oxford PharmaGenesis, UK, for providing medical writing assistance. Funding: The SERENA-4 trial is funded and overseen by AstraZeneca. Clinical trial information: NCT04711252 .
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer
Yin, Jun , Cohen, Romain , Jin, Zhaohui , Liu, Heshan , Pederson, Levi , Adams, Richard , Maughan, Tim , Punt, Cornelis J.A. , Koopman, Miriam , Seymour, Michel , Bokemeyer, Carsten , Heinemann, Volker , Chibaudel, Benoist , Gramont, Aimery de , Shi, Qian , Lenz, Heinz‐Josef , Maughan, Timothy S , Koopman, Miriam , Falcone, Alfredo , Seymour, Matthew T , Bokemeyer, Carsten , Kaplan, Richard , Heinemann, Volker , Zalcberg, John , André, Thierry , De Gramont, Aimery , Shi, Qian , Lenz, Heinz-Josef , Adams, Richard , Jin, Zhaohui , Chibaudel, Benoist , Cohen, Romain , Grothey, Axel , Venook, Alan P. , Cutsem, Eric Van , Falcone, Alfredo , Tebbutt, Niall C. , Díaz‐Rubio, Eduardo , Kaplan, Richard , Yoshino, Takayuki , Zalcberg, John , André, Thierry

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 30, 2021 | Volume: 113 | Issue: 12 | Pages: 1705-1713

10.1093/jnci/djab112 | PMID 34061178 Get It

Abstract Background Unplanned subgroup analyses from several studies have suggested primary tumor sidedness (PTS) as a potential prognostic and predictive parameter in metastatic colorectal cancer (mCRC). We aimed to investigate the impact of PTS on outcomes of mCRC patients. Methods PTS data of 9277 mCRC patients from 12 first-line randomized trials in the ARCAD database were pooled. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox models adjusting for age, sex, performance status, prior radiation/chemotherapy, and stratified by treatment arm. Predictive value was tested by interaction term between PTS and treatment (cetuximab plus chemotherapy vs chemotherapy alone). All statistical tests were 2-sided. Results Compared with right-sided metastatic colorectal cancer patients (n = 2421, 26.1%), left-sided metastatic colorectal cancer patients (n = 6856, 73.9%) had better OS (median = 21.6 vs 15.9 months; adjusted hazard ratio [HRadj] = 0.71, 95% confidence interval [CI] = 0.67 to 0.76; P &lt; .001) and PFS (median = 8.6 vs 7.5 months; HRadj = 0.80, 95% CI = 0.75 to 0.84; P &lt; .001). Interaction between PTS and KRAS mutation was statistically significant (Pinteraction &lt; .001); left-sidedness was associated with better prognosis among KRAS wild-type (WT) (OS HRadj = 0.59, 95% CI = 0.53 to 0.66; PFS HRadj =0.68, 95% CI = 0.61 to 0.75) but not among KRAS mutated tumors. Among KRAS-WT tumors, survival benefit from anti-EGFR was confirmed for left-sidedness (OS HRadj = 0.85, 95% CI = 0.75 to 0.97; P = .01; PFS HRadj = 0.77, 95% CI = 0.67 to 0.88; P &lt; .001) but not for right-sidedness. Conclusions The prognostic value of PTS is restricted to the KRAS-WT population. PTS is predictive of anti-EGFR efficacy, with a statistically significant improvement of survival for left-sidedness mCRC patients. These results suggest treatment choice in mCRC should be based on both PTS and KRAS status.
Secretome Signature of Cardiopoietic Cells Echoed in Rescued infarcted Heart Proteome
Arrell, D. Kent , Crespo‐Diaz, Ruben , Yamada, Satsuki , Jeon, Ryoung‐Hoon , Garmany, Armin , Park, Sungjo , Adolf, Jeffrey P., Livia, Christopher , Hillestad, Matthew L. , Bartúnek, Jozef , Behfar, Atta , Crespo-Diaz, Ruben J, Jeon, Ryounghoon , Terzic, Andre , Behfar, Atta , Livia, Christopher , Bartunek, Jozef , Terzic, André

Mayo Clinic

Stem Cells Translational Medicine | May 28, 2021 | Volume: 10 | Issue: 9 | Pages: 1320-1328

10.1002/sctm.20-0509 | PMID 34047493 Get It

Abstract Stem cell paracrine activity is implicated in cardiac repair. Linkage between secretome functionality and therapeutic outcome was here interrogated by systems analytics of biobanked human cardiopoietic cells, a regenerative biologic in advanced clinical trials. Protein chip array identified 155 proteins differentially secreted by cardiopoietic cells with clinical benefit, expanded into a 520 node network, collectively revealing inherent vasculogenic properties along with cardiac and smooth muscle differentiation and development. Next generation RNA sequencing, refined by pathway analysis, pinpointed miR-146 dependent regulation upstream of the decoded secretome. Intracellular and extracellular integration unmasked commonality across cardio-vasculogenic processes. Mirroring the secretome pattern, infarcted hearts benefiting from cardiopoietic cell therapy restored the disease proteome engaging cardiovascular system functions. The cardiopoietic cell secretome thus confers a therapeutic molecular imprint on recipient hearts, with response informed by predictive systems profiling.
Urticarial vasculitis revealing immunolabelled nucleocapsid protein of SARS‐CoV‐2 in two Brazilian asymptomatic patients: the tip of the COVID‐19 hidden iceberg?
Criado, Paulo Ricardo , Criado, Roberta Fachini Jardim , Gianotti, Raffaele , Abdalla, Beatrice Martinez Zugaib , Pincelli, Thaís , Michalany, Alexandre , Michalany, Nílceo Schwery , Criado, P R , Gianotti, R , Abdalla, Beatrice M Z , Pincelli, T

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | May 25, 2021 | Volume: 35 | Issue: 9 | Pages: No page available

10.1111/jdv.17391 | PMID 34033181 Get It

Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2 : A genome‐wide association study in over 12,000 non‐demented participants
Grenier‐Boley, Benjamin , Simino, Jeannette , Adams, Hieab H.H. , White, Charles C. , Terzikhan, Natalie, Cruchaga, Carlos , Knol, Maria J. , Li, Shuo , Schraen, Susanna, Grove, Megan L. , Satizábal, Claudia L. , Amin, Najaf , Younkin, Steven G., Initiative, Alzheimer's Disease Neuroimaging, Gottesman, Rebecca F., Buée, Luc , Uitterlinden, André G. , DeCarli, Charles , Bressler, Jan , DeStefano, Anita L. , Dartigues, Jean‐François, Boerwinkle, Eric , Tzourio, Christophe , Fornage, Myriam , Jager, Phil De, Reitz, Christiane, Mosley, Thomas H. , Lambert, Jean‐Charles , Duijn, Cornelia M. van , DeCarli, Charles , Younkin, Steven, Cruchaga, Carlos , Adams, Hieab H H , Satizabal, Claudia L , Tzourio, Christophe , van Duijn, Cornelia M , Damotte, Vincent , Lee, Sven J. van der , Chouraki, Vincent Antoine , Tosto, Giuseppe , Berr, Claudine , Initiative, Alzheimer's Disease Neuroimaging, Beiser, Alexa , Knopman, David S. , Yang, Qiong , Ikram, M. Arfan , Amouyel, Philippe , Jager, Philip L. De , Seshadri, Sudha

Mayo Clinic

Alzheimer's & Dementia | May 18, 2021 | Volume: 17 | Issue: 10 | Pages: 1663-1674

10.1002/alz.12333 | PMID 34002480 Get It

Abstract Introduction There is increasing interest in plasma amyloid beta (Aβ) as an endophenotype of Alzheimer's disease (AD). Identifying the genetic determinants of plasma Aβ levels may elucidate important biological processes that determine plasma Aβ measures. Methods We included 12,369 non‐demented participants from eight population‐based studies. Imputed genetic data and measured plasma Aβ1‐40, Aβ1‐42 levels and Aβ1‐42/Aβ1‐40 ratio were used to perform genome‐wide association studies, and gene‐based and pathway analyses. Significant variants and genes were followed up for their association with brain positron emission tomography Aβ deposition and AD risk. Results Single‐variant analysis identified associations with apolipoprotein E ( APOE ) for Aβ1‐42 and Aβ1‐42/Aβ1‐40 ratio, and BACE1 for Aβ1‐40. Gene‐based analysis of Aβ1‐40 additionally identified associations for APP , PSEN2 , CCK , and ZNF397 . There was suggestive evidence for interaction between a BACE1 variant and APOE ε4 on brain Aβ deposition. Discussion Identification of variants near/in known major Aβ‐processing genes strengthens the relevance of plasma‐Aβ levels as an endophenotype of AD.
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
Libiger, Ondrej , Shaw, Leslie M. , Watson, Mark H., Umaña, Kelly L., Biarnes, Michael C., Canet‐Avilés, Rosa M., Breton, Yannick‐André, Cortes, Laetitia, Chelsky, Daniel , Spellman, Daniel S. , Baker, Susan , Raghavan, Nandini, Potter, William Z., (ADNI), Alzheimer's Disease Neuroimaging Initiative, Rosenbaugh, Erin G. , Nairn, Angus C. , Canet-Aviles, Rosa, Jack, Clifford R. , (ADNI), Alzheimer's Disease Neuroimaging Initiative

Mayo Clinic

Alzheimer's & Dementia | May 13, 2021 | Volume: 17 | Issue: 12 | Pages: 1976-1987

10.1002/alz.12353 | PMID 33984181 Get It

Abstract Introduction: Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development. Methods: A targeted, stable isotope, quantitative mass spectrometry‐based investigation of longitudinal changes in concentrations of previously identified candidate biomarkers was performed in cerebrospinal fluid (CSF) of Alzheimer's Disease Neuroimaging Initiative participants who were classified as cognitively normal (CN; n = 76) or with mild cognitive impairment (MCI; n = 111) at baseline. Results: Of the candidate biomarkers, the CSF concentration of neuronal pentraxin 2 (NPTX2), a protein involved in synaptic function, exhibited rates of change that were significantly different between three comparison groups (i.e., CN vs. MCI participants; AD pathology positive vs. negative defined by phosphorylated tau181/amyloid beta1‐42 ratio; and clinical progressors vs. non‐progressors). The rate of change of NPTX2 also significantly correlated with declining cognition. Discussion: CSF NPTX2 concentration is a strong prognostic biomarker candidate of accelerated cognitive decline with potential use as a therapeutic target.